Company intelligence / Profile preview

InnoStar

Shanghai, Shanghai, Chinainnostar.cn ↗

Ownership: Private
Employees: ~1000
Development stage: Other

Overview

InnoStar is a leading Chinese contract research organization specializing in nonclinical and translational research. The company offers comprehensive services including screening/discovery, pharmacodynamics/pharmacokinetics studies, safety evaluation, clinical sample bioanalysis, biomarkers analysis, and more. It has received multiple international certifications (GLP by NMPA/US FDA/Dutch government/AAALAC/CAP) and was listed on the STAR Market of the Shanghai Stock Exchange in September 2024 under stock code 688710. The company operates modern laboratory facilities totaling nearly 60,000 square meters with over one thousand employees.

Modalities: Small moleculesBiologics
Industry: Contract Research Organization

Partnerships

Provides global pharmaceutical companies/research institutions with R&D support

Beyond the preview

Go deeper on InnoStar.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InnoStar.

Explore the full profile